Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||female reproductive organ cancer||not applicable||Durvalumab + Olaparib||Phase I||Actionable||In a Phase I trial, the combination therapy of Imfinzi (durvalumab) and Lynparza (olaparib) resulted in an overall response rate of 17% (2/12) and disease control rate of 83% (10/12) in patients with female reproductive organ cancer (PMID: 28471727).||28471727|
|PubMed Id||Reference Title||Details|
|(28471727)||Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.||Full reference...|